Former Juno Leaders Hans Bishop and Steve Harr Launch Sana Biotechnology, Targeting $800M–$1B Series A Backed by ARCH, Flagship and F-Prime
Former Juno executives Hans Bishop and Steve Harr have launched Sana Biotechnology to develop cell, gene and gene-editing therapies and are reportedly seeking $800 million–$1 billion in Series A funding backed by ARCH Venture Partners, Flagship Pioneering and F-Prime Capital.